Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondilytis- A Cost Per Responder Analysis at 52 Weeks from a Moroccan Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.749
https://www.valueinhealthjournal.com/article/S1098-3015(17)31083-5/fulltext
Title :
Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondilytis- A Cost Per Responder Analysis at 52 Weeks from a Moroccan Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31083-5&doi=10.1016/j.jval.2017.08.749
First page :
A531
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
717